Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
Publisher: New York : Alfred A. Knopf, 2018Description: x, 339 pages ; 25 cmContent type:- text
- unmediated
- volume
- 9781524731656 (hardback)
- 338.7/681761 23
- HD9995.H423 U627 2018
- BUS025000 | BUS027000 | TEC059000
Item type | Current library | Shelving location | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Book | NMC Library | Stacks | HD9995 .H423 U627 2018 (Browse shelf(Opens below)) | 1 | Available | 33039001455673 |
Browsing NMC Library shelves, Shelving location: Stacks Close shelf browser (Hides shelf browser)
HD9993 .E452 C435 2010 Fun Inc. : why gaming will dominate the twenty-first century / | HD9993 .E452 H47 2017 Women in game development : breaking the glass level-cap / | HD9993 .G354 P376 2004 The game makers : the story of Parker Brothers from Tiddledy Winks to Trivial Pursuit / | HD9995 .H423 U627 2018 Bad blood : secrets and lies in a Silicon Valley startup / | HD9999 .C9472 G53 2022 Chokepoint capitalism : how big tech and big content captured creative labor markets and how we'll win them back / | HD9999 .C9473 N49 2007 The Warhol economy : how fashion, art, and music drive New York City / | HD9999 .I492 G35 2017 The four : the hidden DNA of Amazon, Apple, Facebook, and Google / |
Includes bibliographical (pages 305-324) and index.
"The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- Provided by publisher.
There are no comments on this title.